# Phase A bridge acceptance report

Status: accepted for PHA-001 Ralph execution
Date: 2026-04-26
Source board: `docs/plans/kanban-prd-board.md`
PRD: `docs/plans/prd-phase-a-completion-to-implementation-bridge.md`
Test spec: `docs/plans/test-spec-phase-a-completion-to-implementation-bridge.md`

## Tests run

- `python3 <PHA-TB-0 exact-once matrix check>`
- `python3 <PHA-TB-1 canonical merge check>`
- `node --test --import tsx src/views/evidenceChain.test.ts src/views/currentState.test.ts`
- `node --test --import tsx src/views/openLoops.test.ts src/views/timeline.test.ts`
- `node --test --import tsx src/validate.test.ts`
- `npm test`
- `npm run typecheck`
- `npm run check`

## Pass/fail evidence

- PHA-TB-0 exact-once matrix check: exit code 0; `phase count 27`, no missing or duplicate Phase A file paths after adding `clinical-reference/phase-a/a9b-orderset-invocation-synthesis.md` to the matrix.
- PHA-TB-1 canonical merge check: exit code 0; `promoted count 15`, `unmerged []`.
- TB-2 targeted command: `node --test --import tsx src/views/evidenceChain.test.ts src/views/currentState.test.ts` passed with `1..25`, `# pass 25`, `# fail 0`.
- TB-3 targeted command: `node --test --import tsx src/views/openLoops.test.ts src/views/timeline.test.ts` passed with `1..25`, `# pass 25`, `# fail 0`.
- TB-V targeted command: `node --test --import tsx src/validate.test.ts` passed with `1..83`, `# pass 83`, `# fail 0` after adding `V-EXAMFIND-01`.
- Full regression: `npm test` passed with `1..269`, `# pass 269`, `# fail 0`.
- Typecheck: `npm run typecheck` completed with `tsc --noEmit` and exit code 0.
- Chart validation: `npm run check` completed with `0 error(s), 0 warning(s) across 2 patient(s)`.

## Deferred items

- A9b product implementation remains deferred. This pass covers source coverage, canonical accepted-direction triage, and downstream Phase-B ADR signals only.
- Dashboard/cockpit/prototype files and the `playwright` dependency remain an out-of-scope, non-authoritative dirty baseline for PHA-001 because the user was unsure how to dispose of them.
- ADR17 remains non-canonical unless accepted through `ADR17-001`.
- FHIR/adapter/export/legal/audit boundary work remains deferred.
- A9b definition storage, standing-order authentication closure shape, session-identity unification, order-occurrence URI generalization, and A9b profile validation remain Phase-B/ADR work.

## Boundary confirmation

- No pi-agent or pi-sim files were edited.
- No new dependencies were added by this PHA-001 Ralph execution. Pre-existing dashboard/prototype/playwright changes were not expanded.
- TB-2/TB-3 used temp fixtures via test helpers and did not edit `patients/` fixtures.
- TB-2 view support was limited to `src/views/evidenceChain.ts` so action-mediated fulfilled intents can appear in an evidence chain.
- TB-3 fulfillment indexing is action-only, preserving Invariant 10.
- TB-V edits were limited to `src/validate.ts` and `src/validate.test.ts`; `schemas/event.schema.json` was not changed because no narrow existing schema hook was needed.

## Next recommended card

Promote the completed PHA-001 evidence into any release/commit summary. The next product decision should be a separate HITL selection among:

1. A9b/Phase-B ADR lane for order-set invocation implementation details.
2. ADR17 actor/attestation disposition.
3. Dashboard/prototype/playwright disposition as a separate UI/prototype lane.
